March 2022

Now into the third year of the global pandemic, the importance of a functional supply chain for all sectors remains critical. The manufacturing and supply of raw materials needed for not just Covid-19 vaccines, but also the emerging antivirals while the threat of another infectious variant looms over us, is an important consideration.


In the next issue of Pharmaceutical Technology Focus, we will delve into what the data can tell us about the efficiency of the current supply chain system within pharma, and how it may evolve to meet the constantly changing needs. While considering these factors, we will also take a look at how this will affect the industry's quest to decarbonise, as quick worldwide distribution of vaccines and therapeutics becomes the norm.


All this plus the latest trends and innovations in the pharma industry, as well as up-to-date analysis and insight from GlobalData experts.

EDITORIAL

Editor | Manasi Vaidya

Writers | Fiona Barry, Andrew Hillman, Darcy Jimenez, Manasi Vaidya
Magazine Designer | Maria Gimenez

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Filipe Costa, Martina Labaiova, Dimeji Akinkuolie, Will Ingham
Lead Designer | John Hammond 

Publisher | Susanne Hauner
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2022 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Mapping the RNA therapeutics R&D landscape in 2022 Go to article: In this issueGo to article: ContentsGo to article: CSafe GlobalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: HOF SonderanlagenbauGo to article: BEA TechnologiesGo to article: CommentGo to article: Restrictive Medicare coverage spells continued uncertainty for AduhelmGo to article: 2021: a record year for orphan therapiesGo to article: Trikafta/Kaftrio continues to be a game-changer for cystic fibrosis patientsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: In DepthGo to article: Mapping the RNA therapeutics R&D landscape in 2022Go to article: A cloudy day in paradise for pharma tax havens in Cayman Islands & Bermuda?Go to article: Pharmaceutical Technology Excellence Awards 2021 – Winners Announced!Go to article: How technology could transform drug research in 2022Go to article: Anaesthesia drugs worst-hit by US drug shortagesGo to article: Molnar-Institute Company Insight Go to article: Molnar-InstituteGo to article: In DataGo to article: Asia-Pacific sees the largest growth in metabolic disorders-related trials over Go to article: The Middle East has seen the largest growth in infectious disease-related trials over the past decadeGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: BaxterGo to article: EventsGo to article: Next issue